FindTrial
Sign In

JS207

DRUG10 trials

Sponsors

Fudan University, Shanghai Junshi Bioscience Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions

Advanced Colorectal CancerAdvanced Malignant Solid TumorsAdvanced Malignant TumorBreast CancerBreast NeoplasmBreast TumorsEarly-stage Breast CancerHER2-negative Breast Cancer

Phase 1

The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
Active, not recruitingNCT06022250
Shanghai Junshi Bioscience Co., Ltd.Advanced Malignant Tumor
Start: 2023-09-26End: 2026-06-30Updated: 2025-09-18
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors
RecruitingNCT06571422
Shanghai Junshi Bioscience Co., Ltd.Advanced Malignant Solid Tumors
Start: 2024-10-23End: 2027-04-30Target: 93Updated: 2025-02-21
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
RecruitingNCT07466160
Mabwell (Shanghai) Bioscience Co., Ltd.Solid Tumor
Start: 2026-02-11End: 2029-12-31Target: 280Updated: 2026-03-12

Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
RecruitingNCT05582499
Fudan UniversityBreast Cancer, Breast Neoplasm, Breast Tumors +7
Start: 2022-11-01End: 2028-09-30Target: 716Updated: 2025-08-22
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
RecruitingNCT06868836
Shanghai Junshi Bioscience Co., Ltd.Non-squamous Non-small Cell Lung Cancer
Start: 2025-03-30End: 2028-04-04Target: 78Updated: 2026-05-18
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
RecruitingNCT06885385
Shanghai Junshi Bioscience Co., Ltd.Advanced Colorectal Cancer
Start: 2025-04-23End: 2027-02-13Target: 60Updated: 2025-06-24
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
Not yet recruitingNCT06944470
Shanghai Junshi Bioscience Co., Ltd.NSCLC
Start: 2025-04-20End: 2027-12-31Target: 76Updated: 2025-04-25
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
RecruitingNCT06954467
Shanghai Junshi Bioscience Co., Ltd.Hepatocellular Carcinoma
Start: 2025-05-29End: 2028-06-30Target: 72Updated: 2025-07-02
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
RecruitingNCT06969027
Shanghai Junshi Bioscience Co., Ltd.Non-small Cell Lung Cancer
Start: 2025-06-19End: 2027-12-31Target: 84Updated: 2025-07-04
JS212 Combination Therapies in Metastatic Colorectal Cancer
RecruitingNCT07503756
Shanghai Junshi Bioscience Co., Ltd.Metastatic Colorectal Cancer
Start: 2026-04-25End: 2028-03-30Target: 80Updated: 2026-05-05

Related Papers

Abstract CT152: Preliminary results from a phase II trial evaluating the safety and efficacy of JS207, a bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in patients with metastatic colorectal cancer
Cancer Research2026-04-17
Abstract CT159: JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma in a randomized, multicenter, Phase II study
Cancer Research2026-04-17
Abstract GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial
Clinical Cancer Research2025-06-13
Abstract P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial
Clinical Cancer Research2025-06-13
Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial
Therapeutic Advances in Medical Oncology2024-01-017 citations